# Ready-to-Use Therapeutic Foods Fail to Improve Vitamin A and Iron Status Meaningfully during Treatment for Severe Acute Malnutrition in 6–59-Month-old Cambodian Children

Sanne Sigh, Nanna Roos, Chamnan Chhoun, Arnaud Laillou, Frank Wieringa

► To cite this version:

Sanne Sigh, Nanna Roos, Chamnan Chhoun, Arnaud Laillou, Frank Wieringa. Ready-to-Use Therapeutic Foods Fail to Improve Vitamin A and Iron Status Meaningfully during Treatment for Severe Acute Malnutrition in 6–59-Month-old Cambodian Children. Nutrients, 2023, 15 (4), pp.905. 10.3390/nu15040905. [https://doi.org/10.3390/nu15040905]

HAL Id: hal-05408751

https://hal.science/hal-05408751v1

Submitted on 10 Dec 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Article

# Ready-to-Use Therapeutic Foods Fail to Improve Vitamin A and Iron Status Meaningfully during Treatment for Severe Acute Malnutrition in 6–59-Month-old Cambodian Children

Sanne Sigh <fnref n="1" />,<fnref n="2" />,* , Nanna Roos <fnref n="1" /> ID , Chamnan Chhoun <fnref n="2" />, Arnaud Laillou <fnref n="3" /> ID and Frank T. Wieringa <fnref n="4" />,<fnref n="5" /> ID

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Sigh, S.; Roos, N.; Chhoun, C.; Laillou, A.; Wieringa, F.T. Ready-to-Use Therapeutic Foods Fail to Improve Vitamin A and Iron Status Meaningfully during Treatment for Severe Acute Malnutrition in 6-59-Month-old Cambodian Children. *Nutrients* **2023**, *15*, 905. https://doi.org/10.3390/nu15040905

Academic Editors: Kurt Long,
Helen Powell and Johanna Sanchez

Received: 15 January 2023
Revised: 1 February 2023
Accepted: 7 February 2023
Published: 10 February 2023

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

**Abstract:** Severe acute malnutrition (SAM) remains a global health concern. Studies on the impact of ready-to-use therapeutic foods (RUTFs) on micronutrient status during SAM treatment are almost nonexistent. The objective was to investigate the impact of RUTFs on the iron and vitamin A status of 6–59-month-old children receiving SAM treatment. Biomarkers of vitamin A status (retinol-binding protein, RBP), iron status (ferritin and soluble transferrin receptor, sTfR), and inflammation (C-reactive protein, CRP, and alpha-1 acid glycoprotein, AGP) were collected at admission and discharge (week 8) during an RUTF effectiveness trial. Vitamin A deficiency was defined as RBP <0.70 µmol/L, low body iron as body iron (BI) <0 mg/kg and deficient iron stores as ferritin <12 µg/L. Data were available for 110 and 75 children at admission and discharge, respectively. There was no significant difference in haemoglobin, ferritin, sTfR, BI or RBP concentrations between admission and discharge. At discharge, BI was 0.2 mg/kg lower, and there was a tendency towards a slightly lower RBP concentration, but the prevalence of vitamin A deficiency was low at admission and discharge (6% and 3%, respectively). The small impact of both RUTFs on improving vitamin A and iron status during SAM treatment calls for further research on the bioavailability of micronutrients to enhance the effectiveness of SAM treatment on micronutrient status.

**Keywords:** severe acute malnutrition; RUTF; micronutrient; iron; vitamin A; children

1. Introduction

Severe acute malnutrition (SAM) remains a global health concern in many low- and
middle-income countries, with almost 20 million children affected annually, the major-
ity living in South and South-East Asia. SAM is defined as severe wasting (weight-for-
height <−3 Z-scores) and/or a low mid-upper-arm circumference (MUAC, <11.5 cm) or
nutritional oedema regardless of anthropometric indices. SAM contributes significantly to
childhood mortality and morbidity [1,2] and is associated with micronutrient deficiencies,
anaemia and infections [3–9]. Micronutrient deficiencies, including iron, zinc and vita-
min A, increase mortality risk and contribute to a high prevalence of infection, deprived
growth and sub-optimal cognitive development [10]. Moreover, stunting and micronutrient
deficiencies have been estimated to cost USD 266 million annually in Cambodia alone [11].

Children with SAM without complications can be treated with high-energy-dense ready-to-use therapeutic foods [12], which supply all the energy and nutrients required to rehabilitate SAM [13,14]. The effectiveness of RUTFs on weight gain and recovery rates has been well-established, although the weight gains reported are often less than the

<footnote n="1">¹ Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg C, Denmark</footnote>

<footnote n="2">² Department of Fisheries Post-Harvest Technologies and Quality Control, Fisheries Administration, 186 Preah Norodom Boulevard, Phnom Penh 12101, Cambodia</footnote>

<footnote n="3">³ Nutrition Section, UNICEF West and Central Africa Region, Dakar 29720, Senegal</footnote>

<footnote n="4">⁴ UMR QualiSud, Institut de Recherche Pour le Développement (IRD), 34394 Montpellier, France</footnote>

<footnote n="5">⁵ Qualisud, University of Montpellier, Avignon University, CIRAD, Institut Agro, IRD, Université de la Réunion, 34394 Montpellier, France</footnote>

<footnote>* Correspondence: sannesigh@gmail.com; Tel.: +855-(0)95-201-308</footnote>
4 g/kg/day required by the WHO [15–19]. However, studies assessing the effectiveness of RUTFs for SAM treatment in South-East Asia are very limited.

Anaemia is estimated to affect 53% of children <6 years of age in Cambodia [20]. The most important contributor to anaemia is often assumed to be iron deficiency [21], but in the latest national micronutrient survey in Cambodia, the prevalence of iron deficiency among children <5 years of age was only 9% [20]. However, haemoglobinopathies are another important cause of anaemia, particularly in Asia. The prevalence of haemoglobinopathies is high in Cambodia, affecting half of the population [22,23]. Studies on SAM treatment have previously reported a high prevalence of anaemia at admission, for example, 80% in Burkina Faso [24], up to 95% in India [9,25], and 49% in Malawi among children with SAM without complications [26].

In Cambodia, in the same micronutrient survey, the prevalence of vitamin A deficiency (VAD) among children <5 years of age was 9%, slightly below the threshold for a major public health concern. However, a large proportion of children under 5 years of age (29%) had a marginal vitamin A status (RBP < 1.05 µmol/L) [20]. A VAD prevalence of 41% and 98% was reported among malnourished hospitalised children in Brazil and the Congo, respectively [27]. As RUTFs aim, in addition to contributing to weight gain, to also maintain or improve micronutrient status, RUTFs contain, among others, 10–14 mg of iron and 0.8–1.1 mg of vitamin A per 100 g [28]. However, few reports exist on the impact of RUTFs on micronutrient status during recovery from SAM. As rehabilitation from SAM requires catch-up growth, micronutrient requirements during rehabilitation are higher than those required to maintain optimal growth and development during childhood. One recent study found a need to reconsider the RUTF fortification levels of vitamin A and iron to fully restore the micronutrient status of children treated for SAM [29], and another study recommended increasing vitamin B1 content for therapeutic foods [30].

Hence, there is an important gap in the evidence on the impact of RUTFs on micronutrient status in the treatment of SAM. To address this research gap, we investigated the impact on the iron and vitamin A status of 6–59-month-old children treated for SAM without complications with RUTFs.

## 2. Materials and Methods

### 2.1. *Study Design and Setting*

This study was a randomised controlled trial, with data on micronutrient status at admission and discharge after 8 weeks. The trial's main objective was to test the effectiveness of a novel RUTF (NumTrey, a wafer filled with a fish-based paste) against a standard, milk-based RUTF (BP-100TM) for treating SAM among 6–59-month-old Cambodian children. The primary outcomes of the SAM project have been reported elsewhere [31–33]. Sigh et al. 2018 [31] describe the methodology fully.

The intervention trial was conducted from September 2015 until January 2017 at the National Paediatric Hospital in Phnom Penh, Cambodia. The sample size was calculated based on the superiority of either RUTF for the primary outcome, weight gain (g/kg/day). To detect a 10% difference and a standard deviation of 0.7 g/kg/day, a sample size of 49 children in each group was required to achieve 80% power (α = 0.05, two-sided). To account for attrition, 120 children (60 children/group) were enrolled in the trial [31].

### 2.2. *Study Population*

As described previously, the eligibility criterion for this study was 6–59-month-old children with non-complicated SAM or borderline SAM, defined as a weight-for-height z-score (WHZ) $\le -2.8$. Children were also enrolled based on MUAC $\le 115$ mm and/or the presence of nutritional oedema [31]. The inclusion criteria deviated from the WHO definition of SAM to ensure that the children treated for SAM as inpatients could continue outpatient treatment through this trial; hence, the cutoff used in the present trial was adjusted.

Children were not eligible if they had any complications affecting food intake or were participating in other clinical trials. Personal and socio-demographic information was
obtained from caregivers using questionnaires. The age of the children was obtained from either birth certificates or vaccination and growth-monitoring cards or, if unavailable, by interviewing the caregiver. The children received treatment for SAM for 8 weeks. If the children had not recovered within the trial period, they continued treatment under the national SAM treatment program.

## 2.3. Ready-to-Use Therapeutic Foods and Treatment

A local manufacturer (Vissot/Danish Care Foods) produced the local RUTF (NumTrey) [32], and the standard RUTF (BP-100) was imported by UNICEF (Compact, Oslo, Norway). Table 1 shows the micronutrient compositions of the two RUTFs compared with the UN requirements.

<table><caption>**Table 1.** Micronutrient composition of RUTF per 100 g.</caption><thead><tr><th>Product Type</th><th>Standard RUTF</th><th>Local RUTF</th><th>UN Requirements</th></tr></thead><tbody><tr><td>Energy (Kcal)</td><td>526</td><td>506</td><td>520–550</td></tr><tr><td>Vitamin A (mg)</td><td>0.9</td><td>0.8</td><td>0.8–1.1</td></tr><tr><td>Vitamin D (µg)</td><td>18</td><td>11.7</td><td>15–20</td></tr><tr><td>Vitamin E (mg)</td><td>27</td><td>13.3</td><td>≥20</td></tr><tr><td>Vitamin K (µg)</td><td>21</td><td>17.4</td><td>15–30</td></tr><tr><td>Thiamine (vitamin B1) (mg)</td><td>0.5</td><td>0.4</td><td>≥0.5</td></tr><tr><td>Riboflavin (vitamin B2) (mg)</td><td>1.8</td><td>1.1</td><td>≥1.6</td></tr><tr><td>Vitamin C (mg)</td><td>54</td><td>39.3</td><td>≥50</td></tr><tr><td>Vitamin B6 (mg)</td><td>0.7</td><td>0.5</td><td>≥0.6</td></tr><tr><td>Cobalamin (vitamin B12) (µg)</td><td>1.6</td><td>1.1</td><td>≥1.6</td></tr><tr><td>Folic acid (µg)</td><td>225</td><td>249</td><td>≥200</td></tr><tr><td>Niacin (mg)</td><td>5.8</td><td>4.1</td><td>≥5</td></tr><tr><td>Pantothenic acid (mg)</td><td>3</td><td>2.7</td><td>≥3</td></tr><tr><td>Biotin (vitamin B7) (µg)</td><td>70</td><td>94.5</td><td>≥60</td></tr><tr><td>Calcium (mg)</td><td>470</td><td>219</td><td>300–600</td></tr><tr><td>Sodium (mg)</td><td>&lt;290</td><td>8.26</td><td>≤290</td></tr><tr><td>Potassium (mg)</td><td>1100</td><td>773</td><td>1100–1400</td></tr><tr><td>Phosphorus (mg)</td><td>470</td><td>297</td><td>300–600</td></tr><tr><td>Magnesium (mg)</td><td>110</td><td>88</td><td>80–140</td></tr><tr><td>Iron (mg)</td><td>10</td><td>5.8</td><td>10–14</td></tr><tr><td>Zinc (mg)</td><td>12</td><td>7.6</td><td>11–14</td></tr><tr><td>Copper (mg)</td><td>1.5</td><td>1.1</td><td>1.4–1.8</td></tr><tr><td>Selenium (µg)</td><td>25</td><td>20.5</td><td>20–40</td></tr><tr><td>Iodine (µg)</td><td>110</td><td>79.0</td><td>70–140</td></tr></tbody></table>

Abbreviations: RUTF, ready-to-use therapeutic food; kcal, calories; g, gram; mg, milligrams; µg, microgram.

As shown in Table 1, the local RUTF had a slightly lower energy and micronutrient content per 100 g. The wafer wrapping the fish-based paste had a lower nutrient density than the paste. Therefore, during this trial, the children were provided with an RUTF ration, which was calculated based on the nutrition composition of the fish paste without the wafer. This resulted in the distribution of a slightly higher food ration (g/d) to the patients receiving NumTrey. Following the national standards at the time, the food ration distributed to each child was based on the child's weight, calculated to be between 160 and 180 kcal/kg for both RUTFs [34]. The iron and vitamin A content was calculated based on the daily dose per treatment arm described (Table 2).
<table><caption>**Table 2.** Daily food ration and iron and vitamin A content per RUTF by child's weight.</caption><thead><tr><th rowspan="2">Weight (kg)</th><th colspan="5">Standard RUTF</th><th colspan="2">Local RUTF</th></tr><tr><th>RUTF Quantity/Day (bar)</th><th>RUTF Quantity/Day (gram)</th><th>Iron Daily RUTF Dose (mg)</th><th>Vitamin A Daily RUTF Dose (mg)</th><th>RUTF Quantity/Day (Wafer)</th><th>RUTF Quantity/Day (gram)</th><th>Iron Daily RUTF Dose (mg)</th><th>Vitamin A Daily RUTF Dose (mg)</th></tr></thead><tbody><tr><td>3.0–3.4</td><td>2</td><td>~114</td><td>11.4</td><td>1.03</td><td>17</td><td>~170</td><td>9.8</td><td>1.3</td></tr><tr><td>3.5–4.9</td><td>2.5</td><td>~142.5</td><td>14.3</td><td>1.3</td><td>20</td><td>~200</td><td>11.5</td><td>1.5</td></tr><tr><td>5.0–6.9</td><td>4</td><td>~228</td><td>22.8</td><td>2.1</td><td>27</td><td>~270</td><td>15.5</td><td>2.1</td></tr><tr><td>7.0–9.9</td><td>5</td><td>~285</td><td>28.5</td><td>2.6</td><td>40</td><td>~400</td><td>23.0</td><td>3.1</td></tr><tr><td>10.0–14.0</td><td>6</td><td>~342</td><td>34.2</td><td>3.1</td><td>53</td><td>~530</td><td>30.4</td><td>4.1</td></tr></tbody></table>

Abbreviations: RUTF, ready-to-use therapeutic food; kg, kilogram.

## 2.4. Blood Sampling and Laboratory Analyses

At admission (week 0) and discharge (week 8), 4 mL of venous blood was drawn from the cubital vein using a sterile 23G/25G × 3/4" scalp vein set (Vihankook) or a sterile 24G IV cannula needle with a catheter and injection valve (HEALFLONTM, Harsoria Healthcare Private Limited, Udyog Vihar, India) by trained medical staff. Approximately 2 mL of whole blood was collected in a 6 mL trace-element sodium NH heparin vacutainer (VACUETTE®, Greiner Bio-One International GmbH, Frickenhausen, Germany), and the remaining blood was allocated in 2 × 2 mL ethylene diamine tetra acetic vacutainers to analyse haemoglobin concentration (anaemia), haemoglobinopathies and other biomarkers reported elsewhere [33].

At the National Paediatric Hospital, approximately 300 µL of whole blood (EDTA-treated collection tubes) was used to assess haemoglobin concentrations using a haematology analyser (Sysmex Kx-21, Sysmex Corporation, Kobe, Japan, ID. No. NP021 and NP023). The presence of haemoglobinopathies was analysed using electrophoreses (Minicap, SEBIA, Lisses, France) at the National Paediatric Hospital. However, due to a disruption in the capacity to analyse at the hospital, five samples were analysed at the Pasture Institute, Phnom Penh, using the same method and analysis protocol.

The blood samples were stored in a cool box with ice packs while being transported (~30 min) from the hospital to the laboratory at the Department of Fisheries Post-Harvest Technologies and Quality Control for processing. The blood was centrifuged (GlobalRoll®, model 80-2B, Zhejiang, China) for 10 min (2700× g). The plasma was aliquoted into three tubes, with a 0.2 mL Eppendorf PCR tube used for micronutrient status determination. The plasma was stored at <−20 °C until packed with dry ice and shipped to the VitMin laboratory (Willstaett, Germany) for biochemical analyses of iron status (ferritin (FER) and soluble transferrin receptor (sTfR)), vitamin A status (retinol-binding protein (RBP)) and inflammation (C-reactive protein (CRP) and α-1-acid- glycoprotein (AGP)). A combined sandwich ELISA method in duplicate was used to analyse FER, sTfR, RBP, CRP and AGP [35].

## 2.5. Definition of Micronutrient and Health Status

Haemoglobin concentrations were used to diagnose anaemia status using cutoff values recommended by the WHO [36]. A normal haemoglobin genetic pattern was classified as HbA > 70%, HbF ≤ 30% and HbA2 < 2%, and HbA > 95.5%, HbA2 2.0–3.5% and HbF < 5% for 0–23-month-old children and 24–59-month-old children, respectively. All remaining haemoglobin variations were classified as haemoglobinopathies, except for HbE-Heterozygote (HbE between 20 and 30%), which was classified as a separate entity, given the high prevalence [23].

Inflammation was categorised into four groups, that is, healthy and three stages of inflammation, according to Thurnham et al. [37,38]. The inflammation stages were incubation (elevated CRP > 5 mg/L and normal AGP), early convalescence (elevated CRP > 5 mg/L and AGP > 1 g/L) and late convalescence (normal CRP and elevated AGP > 1 g/L). Ferritin and RBP concentrations were corrected for inflammation using the
correction factors derived by Thurnham et al. The ferritin and RBP concentrations of the children without inflammation were not adjusted. Based on a meta-analysis by Turnham et al. 2010 [37], the FER levels were multiplied by 0.77, 0.53 and 0.75 according to the inflammation group, incubation, early convalescence, and late convalescence, respectively. RBP was corrected by factors of 1.15, 1.1.32 and 1.12 for the incubation, early convalescent and late convalescent groups, respectively [38].

No iron stores were defined as FER < 12 µL for children <60 months of age, hence indicating iron deficiency [23]. The cutoff for vitamin A deficiency was defined as an RBP < 0.70 µmol/L [38]. Marginal vitamin A status was defined as RBP 0.70–1.05 µmol/L [39], which is linked with liver stores of retinol [40].

Body iron (BI) was calculated by using the methods devised by Cook et al. [41], using adjusted ferritin concentrations, as follows: Body iron mg/kg = −[log10((sTfR) × 1000/adjusted ferritin) −2.8229]/0.1207. A low BI was defined as BIS < 0 mg/kg [22].

## 2.6. Ethical Considerations

The study protocol was approved by the National Ethical Committee for Health Research of the Ministry of Health, Kingdom of Cambodia (April 2015 Version No. 2). The study was conducted according to the guidelines of the Declaration of Helsinki. Both written and verbal informed consent were obtained from all caregivers. The trial was registered at ClinicalTrials.gov (name: "Comparison of a Locally Produced RUTF With a Commercial RUTF in the Treatment of SAM (FLNS_SAM)"; Trial registration: NCT02907424; URL: https://clinicaltrials.gov/ct2/show/NCT02907424 (accessed on 15 December 2022)).

## 2.7. Statistical Analyses

All data were double-entered into EpiData version 3.1 (The EpiData Association, Odense, Denmark). Statistical analyses were conducted using R studio software (Version 3.4.4, Windows) and SPSS (Version24, IBM). A visual assessment of residuals and a normal probability plot inspection were conducted for all models. Non-normal distributed models were log¹⁰-transformed.

The descriptive statistics are presented as percentages (n) or means (standard deviation, SD). The difference between admission and discharge was analysed using a paired t-test (numeric variables) or Fisher's exact test (categorical variables). The comparison between the two RUTFs from admission to discharge was analysed using general linear modelling (GLM), adjusted for admission values, age and gender with the Emmeans R package, which considers multiple comparisons. The McNemar test was used to compare the statistical differences in the prevalence of deficiency from admission to discharge. A post hoc analysis was used for the children with a high compliance ≥50%. The analyses are reported as means (SD) and p-values. Statistical significance was defined as *p* < 0.05.

# 3. Results

## 3.1. Participants' Characteristics

A total of 121 children were enrolled in the trial. Data were available for 114 and 75 children at admission and discharge, respectively (Figure 1).

The mean age of the children was 21.5 months, and approximately 60% were males (Table 3). Approximately 57% of the children were anaemic, and 37% had a haemoglobin disorder. Of all children, 12.3% and 3.8% had no iron stores and negative body iron, respectively. In comparison, 31.8% had a marginal vitamin A status, and 5.5% were deficient in vitamin A. Inflammation was present among 16% and 39% based on CRP and AGP, respectively, with an overall 40% having inflammation at baseline. The prevalence of anaemia, haemoglobinopathies, iron deficiency, low body iron and vitamin A deficiency was higher among the children randomised to the standard RUTF than among those randomised to the local RUTF. Contrarily, the proportion of inflammation based on CRP was higher among the children randomised to the local RUTF (19%) than among those randomised to the standard RUTF (12%). Two children allocated to the standard RUTF
unfortunately passed away during the study because of progressed HIV infection (one child) and pulmonary tuberculosis (second child) (Figure 1).

<figure><img src="image_5.png" /><figcaption>**Figure 1.** Flowchart of children enrolment into the trial.</figcaption></figure>

<table><caption>**Table 3.** Admission characteristics of children in each group.</caption><thead><tr><th></th><th>Standard RUTF<br>(n = 58)</th><th>Local RUTF<br>(n = 56)</th><th>All<br>Children<br>(n = 114)</th></tr></thead><tbody><tr><td><strong>Socio-demographic parameters</strong></td><td></td><td></td><td></td></tr><tr><td>Age, months</td><td>20.5 (12.6)</td><td>22.6 (14.7)</td><td>21.5 (13.6)</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td>Female, % (n)</td><td>36.2 (21)</td><td>44.6 (25)</td><td>40.4 (46)</td></tr><tr><td>Male, % (n)</td><td>63.9 (37)</td><td>55.4 (31)</td><td>59.6 (68)</td></tr><tr><td><strong>Anthropometrics</strong></td><td></td><td></td><td></td></tr><tr><td>Weight, kg</td><td>7.39 (1.6)</td><td>7.7 (1.9)</td><td>7.51 (1.8)</td></tr><tr><td>Height, cm</td><td>75.1 (9.4)</td><td>77.1 (10.2)</td><td>76.1 (9.8)</td></tr><tr><td>MUAC, mm</td><td>11.8 (0.9)</td><td>11.9 (0.7)</td><td>11.9 (0.8)</td></tr><tr><td>Weight-for-height, z-score</td><td>-3.1 (0.7)</td><td>-3.09 (0.5)</td><td>-3.0 (0.6)</td></tr><tr><td>Weight-for-age, z-score</td><td>-3.4 (0.9)</td><td>-3.3 (0.8)</td><td>-3.3 (0.8)</td></tr><tr><td>Height-for-age, z-score</td><td>-2.4 (1.3)</td><td>-2.2 (1.5)</td><td>-2.3 (1.4)</td></tr><tr><td><strong>Anaemia</strong></td><td></td><td></td><td></td></tr><tr><td>Haemoglobin, g/dl</td><td>10.7 (1.7)</td><td>10.8 (1.3)</td><td>10.8 (1.5)</td></tr><tr><td>Anaemia, % (n) <sup>1,*</sup></td><td>62.3 (33)</td><td>51.0 (25)</td><td>56.9 (58)</td></tr></tbody></table>
<table><caption>**Table 3.** *Cont.*</caption><thead><tr><th></th><th>Standard RUTF<br>(n = 58)</th><th>Local RUTF<br>(n = 56)</th><th>All<br>Children<br>(n = 114)</th></tr></thead><tbody><tr><td><strong>Haemoglobinopathy **</strong></td><td></td><td></td><td></td></tr><tr><td>Hb normal, % (n)</td><td>58.2 (32)</td><td>71.4 (35)</td><td>64.4 (67)</td></tr><tr><td>Hb disorders, % (n)</td><td>42.8 (23)</td><td>28.6 (14)</td><td>35.6 (37)</td></tr><tr><td>HbE-Heterozygote, % (n)</td><td>27.3 (15)</td><td>14.3 (7)</td><td>21.2 (22)</td></tr><tr><td>HbE-Heterozygote/β-thalassemia, % (n)</td><td>3.6 (2)</td><td>4.1 (2)</td><td>3.9 (4)</td></tr><tr><td>HbE-Homozygote, % (n)</td><td>5.5 (3)</td><td>4.1 (1)</td><td>4.8 (5)</td></tr><tr><td>β-thalassemia major, % (n)</td><td>1.8 (1)</td><td>0.0 (0)</td><td>1.0 (1)</td></tr><tr><td>α-thalassemia, % (n)</td><td>0.0 (0)</td><td>2.0 (1)</td><td>1.0 (1)</td></tr><tr><td>α-thalassemia/Harbour spring, % (n)</td><td>0.0 (0)</td><td>2.0 (1)</td><td>1.0 (1)</td></tr><tr><td>Hb-Other, % (n)</td><td>3.6 (2)</td><td>2.0 (1)</td><td>3.0 (3)</td></tr><tr><td><strong>Iron status *</strong></td><td></td><td></td><td></td></tr><tr><td>Ferritin, µg/L</td><td>40.3 (30.0)</td><td>41.4 (28.1)</td><td>40.8 (28.9)</td></tr><tr><td>sTfR, mg/L</td><td>10.2 (7.4)</td><td>10.1 (9.0)</td><td>10.1 (8.2)</td></tr><tr><td>BI, mg/kg</td><td>3.5 (4.6)</td><td>4.1 (3.8)</td><td>3.8 (4.2)</td></tr><tr><td>Iron deficiency, % (n)</td><td>19.3 (11)</td><td>5.7 (3)</td><td>12.7 (14)</td></tr><tr><td>Low BI, % (n)</td><td>17.5 (10)</td><td>11.3 (6)</td><td>14.5 (16)</td></tr><tr><td><strong>Vitamin A status *</strong></td><td></td><td></td><td></td></tr><tr><td>RBP, µmol/L</td><td>1.2 (0.5)</td><td>1.4 (0.6)</td><td>1.3 (0.6)</td></tr><tr><td>Marginal vitamin A status, % (n)</td><td>38.6 (22)</td><td>24.5 (13)</td><td>31.8 (35)</td></tr><tr><td>Vitamin A deficiency, % (n)</td><td>7 (4)</td><td>3.8 (2)</td><td>5.5 (6)</td></tr><tr><td><strong>Inflammation status *</strong></td><td></td><td></td><td></td></tr><tr><td>CRP, mg/L</td><td>4.0 (10.8)</td><td>3.1 (5.4)</td><td>3.6 (8.1)</td></tr><tr><td>CRP, >5 mg/L, % (n)</td><td>12.3 (7)</td><td>18.9 (10)</td><td>15.5 (17)</td></tr><tr><td>AGP, g/L</td><td>1.1 (0.9)</td><td>1.0 (0.6)</td><td>1.1 (0.8)</td></tr><tr><td>AGP, >1 g/L, % (n)</td><td>38.6 (22)</td><td>39.6 (21)</td><td>39.1 (43)</td></tr></tbody></table>

Data are reported as percentages (n) or means (SD). ¹ Anaemia cutoff is age- and sex-dependent. Abbreviations: MUAC, mid-upper-arm circumference; sTfR, soluble transferrin receptor; BI, body store; CRP, C-reactive protein; AGP, α₁-acid glycoprotein. * No micronutrient data for one child (standard RUTF) and three children (local RUTF), hence a total of 4 children. ** Missing data from 10 children (n = 3 standard RUTF, and n = 7 local RUTF).

## 3.2. Effectiveness of SAM Treatment on Micronutrient Status

There was no significant change in haemoglobin, ferritin or sTfR concentrations between admission and discharge, with the concentrations of the biomarkers for micronutrient status similar to or even lower at discharge than at admission. In a sub-analysis of the children with a high compliance with the RUTF treatment (>50%, n = 31), no significant differences in biomarker concentrations between admission and discharge were observed, but the overall trend was towards a better micronutrient status.

There were no significant differences in the prevalence of iron or vitamin A deficiency or anaemia between admission and discharge after 8 weeks of treatment. The prevalence of children with a marginal vitamin A deficiency slightly increased from 31.8% to 32.9% from admission to discharge (p = 0.065) (Table 4). The prevalence of iron deficiency was reduced by 6 percent in the small group of children with a high compliance with the treatment, but no significant difference was seen (p = 0.63, Table 5).
<table><caption>**Table 4.** Vitamin, mineral and inflammation status during the SAM effectiveness trial.</caption><caption>6-59-Month-Old Children<br>Admission Mean Age of 21.5 Months</caption><thead><tr><th rowspan="2">Biomarker</th><th colspan="2">Admission<br>(n = 110)</th><th colspan="2">Discharge<br>(n = 75)</th><th rowspan="2">p-Value <sup>1</sup></th></tr><tr><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>Haemoglobin, g/dl</td><td>10.8</td><td>1.5</td><td>11.0</td><td>1.6</td><td>0.27</td></tr><tr><td>Ferritin, µg/L</td><td>40.8</td><td>28.9</td><td>37.0</td><td>23.6</td><td>0.74</td></tr><tr><td>sTfR, mg/L</td><td>10.1</td><td>8.2</td><td>9.8</td><td>8.6</td><td>0.46</td></tr><tr><td>BI, mg/kg</td><td>3.8</td><td>4.2</td><td>3.6</td><td>3.8</td><td>0.90</td></tr><tr><td>RBP, µmol/L</td><td>1.3</td><td>0.6</td><td>1.2</td><td>0.6</td><td>0.36</td></tr><tr><td>CRP, mg/L</td><td>3.6</td><td>8.6</td><td>2.6</td><td>5.7</td><td>0.39</td></tr><tr><td>AGP, g/L</td><td>0.96</td><td>0.69</td><td>0.79</td><td>0.57</td><td>0.08</td></tr><tr><td>Iron deficiency, %</td><td colspan="2">12.5</td><td colspan="2">9.6</td><td>1.00</td></tr><tr><td>Low BI, %</td><td colspan="2">14.5</td><td colspan="2">16.4</td><td>0.73</td></tr><tr><td>Marginal vitamin A, %</td><td colspan="2">31.8</td><td colspan="2">32.9</td><td>0.65</td></tr><tr><td>Vitamin A deficiency, %</td><td colspan="2">5.5</td><td colspan="2">2.7</td><td>1.00</td></tr><tr><td>Anaemia, %</td><td colspan="2">56.9</td><td colspan="2">52.0</td><td>0.55</td></tr></tbody></table>

Abbreviations: sTfR, soluble transferrin receptor; BI, body iron; RBP, retinol-binding protein; CRP, C-reactive protein; AGP, α₁-glycoprotein; SE, standard error. *p* < 0.05 is considered a statistically significant difference. ¹ *p*-values are for comparing admission to discharge with GLM repeated measures variables and McNemar for deficiency.

<table><caption>**Table 5.** Vitamin, mineral and inflammation status during the SAM effectiveness trial among children with (>50%) high compliance.</caption><caption>6-59-Month-Old Children<br>Admission Mean Age of 19.7 Months</caption><thead><tr><th rowspan="2">Biomarker</th><th colspan="2">Admission<br>(n = 31)</th><th colspan="2">Discharge<br>(n = 31)</th><th rowspan="2">p-Value <sup>1</sup></th></tr><tr><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th></tr></thead><tbody><tr><td>Haemoglobin, g/dl</td><td>10.7</td><td>1.3</td><td>10.9</td><td>1.2</td><td>0.25</td></tr><tr><td>Ferritin, µg/L</td><td>32.0</td><td>27.4</td><td>33.5</td><td>19.9</td><td>0.75</td></tr><tr><td>sTfR, mg/L</td><td>12.2</td><td>10.7</td><td>10.1</td><td>8.8</td><td>0.16</td></tr><tr><td>BI, mg/kg</td><td>2.3</td><td>5.0</td><td>3.3</td><td>4.1</td><td>0.19</td></tr><tr><td>RBP, µmol/L</td><td>1.24</td><td>0.44</td><td>1.33</td><td>0.77</td><td>0.55</td></tr><tr><td>CRP, mg/L</td><td>4.3</td><td>10.7</td><td>3.5</td><td>7.9</td><td>0.74</td></tr><tr><td>AGP, g/L</td><td>1.0</td><td>0.74</td><td>0.9</td><td>0.69</td><td>0.69</td></tr><tr><td>Iron deficiency, %</td><td colspan="2">19.4</td><td colspan="2">12.9</td><td>0.63</td></tr><tr><td>Low BI, %</td><td colspan="2">22.6</td><td colspan="2">19.4</td><td>1.00</td></tr><tr><td>Marginal vitamin A, %</td><td colspan="2">32.3</td><td colspan="2">22.5</td><td>0.51</td></tr><tr><td>Vitamin A deficiency, %</td><td colspan="2">6.4</td><td colspan="2">3.2</td><td>1.00</td></tr><tr><td>Anaemia, %</td><td colspan="2">56.7</td><td colspan="2">54.8</td><td>1.00</td></tr></tbody></table>

Abbreviations: sTfR, soluble transferrin receptor; BI, body iron; RBP, retinol-binding protein; CRP, C-reactive protein; AGP, α₁-glycoprotein; SE, standard error. *p* < 0.05 is considered a statistically significant difference. ¹ *p*-values are for comparing admission to discharge with GLM repeated measures variables and McNemar for deficiency.

### 3.3. *Comparison between RUTFs*

As there were minor differences in the composition, including in the iron and vitamin A content, of the two RUTFs, vitamin A and iron status changes over the 8 weeks of treatment were compared between the two RUTFs (Table 6). No statistical difference in the changes in micronutrient status was found between the two products; therefore, the results for the two RUTFs were combined.
<table><caption>**Table 6.** Estimated micronutrient and inflammation status at discharge from SAM treatment per RUTF.</caption><thead><tr><th rowspan="2">Biomarker</th><th colspan="2">Standard RUTF<br>(n = 36)</th><th colspan="2">Local RUTF<br>(n = 33)</th><th colspan="3">Difference between Treatments (Compared to Control)</th></tr><tr><th>Mean</th><th>SD</th><th>Mean</th><th>SD</th><th>Estimated Difference</th><th>SE</th><th>p-Value</th></tr></thead><tbody><tr><td>Haemoglobin, g/dl</td><td>11.4</td><td>1.8</td><td>10.5</td><td>1.1</td><td>-0.58</td><td>0.35</td><td>0.10</td></tr><tr><td>Ferritin, µg/L</td><td>36.5</td><td>24.1</td><td>37.2</td><td>24.7</td><td>-0.20</td><td>5.4</td><td>0.98</td></tr><tr><td>sTfR, mg/L</td><td>9.7</td><td>7.2</td><td>10.3</td><td>10.4</td><td>-0.04</td><td>2.1</td><td>0.99</td></tr><tr><td>BI, mg/kg</td><td>3.4</td><td>4.0</td><td>3.6</td><td>3.9</td><td>+0.49</td><td>0.93</td><td>0.60</td></tr><tr><td>RBP, µmol/L</td><td>1.23</td><td>0.75</td><td>1.28</td><td>0.37</td><td>+0.06</td><td>0.11</td><td>0.58</td></tr></tbody></table>

Abbreviations: sTfR, soluble transferrin receptor; BI, body iron; RBP, retinol-binding protein; CRP, C-reactive protein; AGP, α₁-glycoprotein; SE, standard error. *p* < 0.05 is considered a statistically significant difference.

## 4. Discussion

In this study, we aimed to assess the impact of RUTFs on the micronutrient status of children with severe acute malnutrition. The prevalence of anaemia and the deficiencies of iron and vitamin A were similar to those reported in the national micronutrient survey but lower than those expected in children with severe acute malnutrition. Indeed, the same pattern of a relatively low prevalence of iron and vitamin A deficiency combined with a high prevalence of anaemia, as found in the national micronutrient survey [20], was present in our study population. Surprisingly, neither iron nor vitamin A status improved significantly over the 8-week treatment. To ascertain that low compliance with the treatment did not underlie this lack of impact, we conducted a sub-group analysis in children consuming >50% of the provided RUTF. However, this sub-group analysis yielded similar results, with only minor shifts in micronutrient status between admission and discharge from treatment. The prevalence of anaemia remained high, above 50%, and it hardly changed over the 2-month treatment (from 57% to 52%, *p* = 0.55). Iron deficiency could only partly explain the high anaemia prevalence, as only 10% of the children had IDA at admission. A study conducted among children receiving treatment for SAM in Burkina Faso observed that anaemia decreased significantly from 78% to 56% from admission to discharge [29]. Similarly, a study with a 12-week treatment of moderate acute malnutrition found a reduction in anaemia from 70% at admission to 53% at discharge [42]. Anaemia has a multi-factorial causality; besides iron, many other factors are involved, both nutritional and non-nutritional. RUTFs supply an extensive range of vitamins and minerals, including those implicated in the aetiology of anaemia (e.g., vitamins A, B2, B6, B9, B12, and copper and zinc) [43–47]. Hence, it could be assumed that all forms of nutritional anaemia would be addressed during treatment with RUTF. The lack of impact on the haemoglobin concentrations in the Cambodian children could thus be due to the fact that non-nutritional causes, such as haemoglobinopathies, were the main cause of anaemia in the present study [22].

During the present study, the compliance with RUTF intake was lower than expected and desired [31], which influenced the intake of micronutrients and, hence, the possible increase in micronutrient status between admission and discharge. In an ad hoc analysis of the data obtained from the present study (data not presented), even in the small sample of children with a high compliance, no indication or significant impact on micronutrient status was found. Hence, it appears that the RUTFs provided insufficient amounts of micronutrients to improve micronutrient status, confirming the similar observations made by Kangas et al. [29]. One possible explanation could be that the bioavailability of iron and vitamin A is low due to inflammation in the gastrointestinal tract, which markers of systemic inflammation, such as CRP and AGP, might not reflect. Small intestinal inflammation (environmental enteric dysfunction and environmental enteropathy) is widespread in low- and middle-income countries and strongly associated with malnutrition, for example, stunting and wasting [48–52], and, hence, environmental enteric dysfunction and enteropathy are likely to influence and limit the effectiveness of fortified foods, such as RUTFs, in improving micronutrient status in malnourished children.
Both the local and standard RUTFs contain ~2 mg more zinc than iron, so it could be speculated that the low increase in iron in this trial was caused by micronutrient interactions between the different nutrients resulting in an inhibited uptake of certain nutrients; for example, zinc and iron compete during intestinal absorption when they are ingested simultaneously, which is the case when children are treated with RUTFs [53]. An excess zinc intake has been found to inhibit zinc absorption and vice versa [54,55]. However, the evidence is conflicting, as well as the discussions on the definitions of interactions between micronutrients [56].

The WHO states that 6–59-month-old children with SAM do not require a high dose of vitamin A supplements, as they receive RUTFs that already contain sufficient vitamin A [12]. This study indicates that vitamin A intake during the RUTF rehabilitation of SAM may be insufficient with the current levels of fortification of the RUTF products.

In particular, iron has been tested in alternative RUTF formulations containing more iron than standard RUTFs. Administering alternative RUTFs to children containing higher amounts of iron (31–35 mg/100 g) compared with standard RUTFs (11 g/100 g) resulted in significantly lower rates of anaemia among children treated with the alternative RUTFs (12–18%) compared to standard RUTF (25%) at discharge [26]. This may indicate that children in countries with high anaemia and iron deficiency rates might benefit from RUTF formulations with a higher iron content. However, in the context of the present study in Cambodia, the higher iron content of the RUTFs would probably have made little difference, given our subjects' low prevalence of iron deficiency. Moreover, increasing iron intake in SAM requires careful consideration, as several issues may arise, including the negative effects of high iron intake on the human microbiome. Hence, increasing iron content in RUTFs might not apply to countries such as Cambodia, where genetically inherited haemoglobinopathies are common among its population [20]. Another concern with iron is that iron is a pro-oxidative element, which can have negative effects on biological systems at even moderate dosages; for example, beyond altering the gut microbiota, there are some reports on decreased growth (linear and weight); increased illness; and, as mentioned earlier, interactions with other trace elements, such as zinc and copper, and impaired cognitive and motor development [57].

Studies reporting changes in vitamin A status during the RUTF treatment of children with SAM without complications are scarce. There was no impact on circulating RBP concentrations in the present study, although the prevalence of vitamin A deficiency decreased from 6% at admission to 3% at discharge. The prevalence of vitamin A deficiency was considerably higher in a study from Burkina Faso, where a decrease in VAD from 25% at admission to 9% at discharge was found [29]. A National survey in Cambodia conducted a year previous to the study showed that 9% of <5-year-old children suffered from VAD [20]. However, the study did not appear to adjust serum retinol for inflammation. It may have overestimated VAD prevalence [58]. RBP is depressed during infection and inflammation, as it is a negative acute-phase reactant [58].

Unfortunately, although RBP or circulating retinol concentrations do indicate deficiency (<0.70 µmol/L) and marginal vitamin A status (<1.05 µmol/L), they do not reflect the true vitamin A status at higher concentrations. Liver vitamin A concentration is considered the golden standard for vitamin A status because retinol concentration is under homeostatic control to protect humans against toxic concentrations and is used for growth and cellular differentiation in humans.

## *Strengths and Limitations*

Compliance with RUTF intake was generally low during the effectiveness study. As the study ended after 8 weeks of treatment, not all children might have fully recovered at the time of discharge. The children continued the treatment following the national protocol, but data and biomarkers were not collected after week 8. At the endline, data from 35 children were not collected for various reasons but mainly due to non-compliance with the treatment. Two children passed away due to pre-existing illnesses. Others dropped out
or provided insufficient blood collection. As severely ill children are likely to have a worse micronutrient status, discharge data might underestimate the deficiencies at discharge, representing a "best-case" scenario. Moreover, we did not collect data on the provision of high-dose vitamin A capsules (HDVACs) among the patients beyond the treatment received at the hospital. Although the use of HDVACs is limited in Cambodia, we cannot exclude the possibility that some children might have received an HDVAC shortly before admission into the study. Finally, the content of vitamin A within the RUTFs could have decreased during storage, as vitamin A can be unstable, thereby reducing the impact on vitamin A status. However, vitamin A appeared to be relatively stable in this study [59]. It is important to note that the study presents secondary outcomes, so the sample size calculation was not calculated to assess differences in micronutrient status.

Despite these limitations, the study successfully obtained data for biomarkers of a large majority of the children, which allows for a confident estimation of iron status and vitamin A at admission, discharge and change between the two assessment points.

**5. Conclusions**

In conclusion, this study found that both standard and locally produced RUTFs failed to have a meaningful impact on anaemia prevalence and iron and vitamin A status, despite providing a fully fortified food product, and micronutrient status remained sub-optimal after 8 weeks of SAM treatment. The RUTFs may prevent children with SAM from becoming vitamin A deficient to some extent. The little impact of both RUTFs in improving iron and vitamin A during the 8 weeks of SAM treatment calls for further research on how to improve the effectiveness of SAM treatment on micronutrient status to ensure that vulnerable children receive all essential nutrients during treatment.

**Author Contributions:** Conceptualisation, S.S., N.R., F.T.W., C.C. and A.L.; methodology, S.S., N.R., F.T.W., C.C. and A.L.; validation, S.S., N.R., F.T.W., C.C. and A.L.; formal analysis, S.S. and F.T.W.; investigation, S.S.; resources, S.S., N.R., F.T.W., C.C. and A.L.; data curation, S.S.; writing—original draft preparation, S.S.; writing—review and editing, S.S., N.R., F.T.W., C.C. and A.L.; visualisation, S.S. and F.T.W.; supervision, N.R., F.T.W., C.C. and A.L.; project administration, S.S.; funding acquisition, S.S., N.R., F.T.W., C.C. and A.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by UNICEF's national committees (Australia, Korea and Hong Kong); Institut de Recherché pour le Développement, France; the University of Copenhagen, Denmark; and Neys-van Hoogstraten Foundation, The Netherlands (grant ID: CA271).

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of The National Ethical Committee for Health Research, Ministry of Health, Cambodia (protocol code No. 2 and April 2015) for studies involving humans.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** The authors would like to thank all the children and their caregivers who participated in the trial and the dedicated data collection team. A deep and sincere thanks to the National Paediatric Hospital for their collaboration and support during the trial. Moreover, thanks to Lyndon Paul (Vissot) for this work on product development.

**Conflicts of Interest:** The authors declare no conflict of interest. The opinions and statements in this article are those of the authors. They do not necessarily reflect the official policies or opinions of the organisations they belong to. The funders had no role in the study.
Abbreviations

<table><tr><td>AGP</td><td>α₁-acid glycoprotein</td></tr><tr><td>BI</td><td>Body iron</td></tr><tr><td>CRP</td><td>C-reactive protein</td></tr><tr><td>FER</td><td>Ferritin</td></tr><tr><td>HDVAC</td><td>High-dose vitamin A capsule</td></tr><tr><td>MUAC</td><td>Mid-upper-arm circumference</td></tr><tr><td>RBP</td><td>Retinol-binding protein</td></tr><tr><td>RUTF</td><td>Ready-to-use therapeutic foods</td></tr><tr><td>SAM</td><td>Severe acute malnutrition</td></tr><tr><td>sTfR</td><td>Soluble transferrin receptor</td></tr><tr><td>SD</td><td>Standard deviation</td></tr><tr><td>WHO</td><td>World Health Organization</td></tr><tr><td>WHZ</td><td>Weight-for-height z-score</td></tr></table>

References

1. Black, R.E.; Victora, C.G.; Walker, S.P.; Bhutta, Z.A.; Christian, P.; De Onis, M.; Ezzati, M.; Grantham-McGregor, S.; Katz, J.; Martorell, R.; et al. Maternal and Child Undernutrition and Overweight in Low-Income and Middle-Income Countries. *Lancet* **2013**, *382*, 427–451. [CrossRef] [PubMed]

2. Lapidus, N.; Luquero, F.J.; Gabaulaud, V.; Shepherd, S.; Grais, R.F. Prognostic Accuracy of WHO Growth Standards to Predict Mortality in a Large-Scale Nutritional Program in Niger. *PLoS Med.* **2009**, *6*, e1000039. [CrossRef] [PubMed]

3. Saurabh, K.; Ranjan, S.; Narayan, J.P. Co-Morbidities and Micronutrient Deficiencies in Children with Severe Acute Malnutrition Fasciola Buski Infestation in Children View Project Co-Morbidities and Micronutrient Deficiencies in Children with Severe Acute Malnutrition. *Int. J. Contemp. Pediatr.* **2017**, *44*, 1225–1227. [CrossRef]

4. Smit, E.N.; Muskiet, F.a.J.; Boersma, E.R. The Possible Role of Essential Fatty Acids in the Pathophysiology of Malnutrition: A Review. *Prostaglandins Leukot. Essent. Fat. Acids* **2004**, *71*, 241–250. [CrossRef]

5. Bachou, H.; Tylleskär, T.; Kaddu-Mulindwa, D.H.; Tumwine, J.K. Bacteraemia among Severely Malnourished Children Infected and Uninfected with the Human Immunodeficiency Virus-1 in Kampala, Uganda. *BMC Infect. Dis.* **2006**, *6*, 160. [CrossRef]

6. Babirekere-Iriso, E.; Musoke, P.; Kekitiinwa, A. Bacteraemia in Severely Malnourished Children in an HIV-Endemic Setting. *Ann. Trop. Paediatr.* **2006**, *26*, 319–328. [CrossRef]

7. Jones, K.D.J.; Berkley, J.A. Severe Acute Malnutrition and Infection. *Paediatr. Int. Child Health* **2014**, *34*, S1–S29. [CrossRef]

8. Jones, K.D.; Berkley, J.A. Childhood Malnutrition: Toward an Understanding of Infections, Inflammation, and Antimicrobials. *Food Nutr. Bull.* **2014**, *35*, 64–70. [CrossRef]

9. Thakur, N.; Chandra, J.; Pemde, H.; Singh, V. Anemia in Severe Acute Malnutrition. *Nutrition* **2014**, *30*, 440–442. [CrossRef]

10. Bailey, R.L. The Epidemiology of Global Micronutrient Deficiencies. *Ann. Nutr. Metab.* **2015**, *66*, 22–33. [CrossRef]

11. Moench-Pfanner, R.; Silo, S.; Laillou, A.; Wieringa, F.; Hong, R.; Hong, R.; Poirot, E.; Bagriansky, J. The Economic Burden of Malnutrition in Pregnant Women and Children under 5 Years of Age in Cambodia. *Nutrients* **2016**, *8*, 292. [CrossRef]

12. WHO. *Guideline: Updates on the Management of Severe Acute Malnutrition in Infants and Children*; World Health Organization: Geneva, Switzerland, 2013; pp. 1–123.

13. De Pee, S.; Bloem, M.W. Current and Potential Role of Specially Formulated Foods and Food Supplements for Preventing Malnutrition among 6–23 Month Old Children and Treating Moderate Malnutrition among 6–59 Months Old Children. *Food Nutr. Bull.* **2009**, *30*, 1–40. [CrossRef]

14. Manary, M.J. Local Production and Provision of Ready To Use Therapeutic Food (Rutf) Spread for the Treatment of Severe Childhood Malnutrition. *Food Nutr. Bull.* **2006**, *27*, 83–89. [CrossRef]

15. Ciliberto, M.; Manary, M.; Ndekha, M.; Briend, A.; Ashorn, P. Home-Based Therapy for Oedematous Malnutrition with Ready-to-Use Therapeutic Food. *Acta Paediatr. Int. J. Paediatr.* **2006**, *95*, 1012–1015. [CrossRef]

16. Ravichandra, K.R.; Behera, N. Locally Prepared Ready to Use Therapeutic Food for the Treatment of Children with Severe Acute Malnutrition: A Randomized Controlled Trial. *Int J Contemp Pediatr.* **2017**, *4*, 1491–1495.

17. Diop, E.H.I.; Dossou, N.I.; Ndour, M.M.; Briend, A.; Wade, S. Comparison of the Efficacy of a Solid Ready-to-Use Food and a Liquid, Milk-Based Diet for the Rehabilitation of Severely Malnourished Children: A Randomized Trial. *Am. J. Clin. Nutr.* **2003**, *78*, 302–307. [CrossRef]

18. Sandige, H.; Ndekha, M.J.; Briend, A.; Ashorn, P.; Manary, M.J. Home-Based Treatment of Malnourished Malawian Children with Locally Produced or Imported Ready-to-Use Food. *J. Pediatr. Gastroenterol. Nutr.* **2004**, *39*, 141–146. [CrossRef]

19. Schoonees, A.; Mj, L.; Musekiwa, A.; Nel, E.; Volmink, J. Ready-to-Use Therapeutic Food (RUTF) for Home-Based Nutritional Rehabilitation of Severe Acute Malnutrition in Children from Six Months to Five Years of Age (Review). *Cochrane* **2019**, *5*, CD009000. [CrossRef]
20. National Institute of Statistics, Directorate General for Health, and ICF International. *Cambodia Demographic and Health Survey 2014*; National Institute of Statistics, Directorate General for Health, and ICF International: Phnom Penh, Cambodia; Rockville, MD, USA, 2015; pp. 1–479.

21. Kassebaum, N.J.; Jasrasaria, R.; Naghavi, M.; Wulf, S.K.; Johns, N.; Lozano, R.; Regan, M.; Weatherall, D.; Chou, D.P.; Eisele, T.P.; et al. A Systematic Analysis of Global Anemia Burden from 1990 to 2010. *Blood* **2014**, *123*, 615–625. [CrossRef]

22. Wieringa, F.T.; Dahl, M.; Chamnan, C.; Poirot, E.; Kuong, K.; Sophonneary, P.; Sinuon, M.; Greuffeille, V.; Hong, R.; Berger, J.; et al. The High Prevalence of Anemia in Cambodian Children and Women Cannot Be Satisfactorily Explained by Nutritional Deficiencies or Hemoglobin Disorders. *Nutrients* **2016**, *8*, 348. [CrossRef]

23. Karakochuk, C.D.; Whitfield, K.C.; Barr, S.I.; Lamers, Y.; Devlin, A.M.; Vercauteren, S.M.; Kroeun, H.; Talukder, A.; Mclean, J.; Green, T.J. Genetic Hemoglobin Disorders Rather Than Iron Deficiency Are a Major Predictor of Hemoglobin Concentration in Women of Reproductive Age in Rural Prey Veng, Cambodia. *J. Nutr.* **2015**, *145*, 134–142. [CrossRef] [PubMed]

24. Savadogo, L.G.B.; Zoetaba, I.; Ilboudo, B.; Kinda, M.; Donnen, P. Impact of Anemia on Mortality and Nutritional Recovery among Hospitalized Severely Malnourished Children in Burkina Faso. *Open J. Pediatr.* **2014**, *4*, 115–120. [CrossRef]

25. Arya, A.K.; Kumar, P.; Midha, T.; Singh, M. Co-Morbidities in Children with Severe Acute Malnutrition—A Tertiary Care Centre Experience. *Int. J. Contemp. Pediatr.* **2017**, *4*, 1577. [CrossRef]

26. Akomo, P.; Bahwere, P.; Murakami, H.; Banda, C.; Maganga, E.; Kathumba, S.; Sadler, K.; Collins, S. Soya, Maize and Sorghum Ready-to-Use Therapeutic Foods Are More Effective in Correcting Anaemia and Iron Deficiency than the Standard Ready-to-Use Therapeutic Food: Randomized Controlled Trial. *BMC Public Health* **2019**, *19*, 806. [CrossRef]

27. Caminha, C.; Falbo, R.; Grande, K. Serum Retinol Concentrations in Hospitalized Severe Protein-Energy Malnourished Children. *J. Trop. Pediatr.* **2008**, *54*, 248–252. [CrossRef]

28. World Health Organization; World Food Programme; United Nation System Standing Committee on Nutrition; The United Nations Children's Fund. *Community-Based Management of Severe Acute Malnutrition*; World Health Organization: Geneva, Switzerland, 2007; pp. 1–8.

29. Kangas, S.T.; Salpeteur, C.; Nikiema, V.; Talley, L.; Briend, A.; Ritz, C.; Friis, H.; Kaestel, P. Vitamin A and Iron Status of Children before and after Treatment of Uncomplicated Severe Acute Malnutrition. *Clin. Nutr.* **2020**, *39*, 3512–3519. [CrossRef]

30. Hiffler, L.; Adamolekun, B.; Fischer, P.R.; Fattal-Vavleski, A. Thiamine Content of F-75 Therapeutic Milk for Complicated Severe Acute Malnutrition: Time for a Change? *Ann. N. Y. Acad. Sci.* **2017**, *1404*, 20–26. [CrossRef]

31. Sigh, S.; Roos, N.; Chamnan, C.; Laillou, A.; Prak, S.; Wieringa, F.T. Effectiveness of a Locally Produced, Fish-Based Food Product on Weight Gain among Cambodian Children in the Treatment of Acute Malnutrition: A Randomized Controlled Trial. *Nutrients* **2018**, *10*, 909. [CrossRef]

32. Sigh, S.; Roos, N.; Sok, D.; Borg, B.; Chamnan, C.; Laillou, A.; Dijkhuizen, M.A.; Wieringa, F.T. Development and Acceptability of Locally Made Fish-Based, Ready-to-Use Products for the Prevention and Treatment of Malnutrition in Cambodia. *Food Nutr. Bull.* **2018**, *39*, 420–434. [CrossRef]

33. Sigh, S.; Lauritzen, L.; Wieringa, F.T.; Laillou, A.; Chamnan, C.; Angkeabos, N.; Moniboth, D.; Berger, J.; Stark, K.D.; Roos, N. Whole-Blood PUFA and Associations with Markers of Nutritional and Health Status in Acutely Malnourished Children in Cambodia. *Public Health Nutr.* **2020**, *23*, 974–986. [CrossRef]

34. National Nutrition Program. *National Interim Guidelines for the Management of Acute Malnutrition*; National Nutrition Program, Ministry of Health: Phnom Penh, Cambodia, 2011; pp. 1–77.

35. Erhardt, J.G.; Estes, J.E.; Pfeiffer, C.M.; Biesalski, H.K.; Craft, N.E. Combined Measurement of Ferritin, Soluble Transferrin Receptor, Retinol Binding Protein, and C-Reactive Protein by an Inexpensive, Sensitive, and Simple Sandwich Enzyme-Linked Immunosorbent Assay Technique. *J. Nutr.* **2004**, *134*, 3127–3132. [CrossRef]

36. World Health Organization. *Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity*; World Health Organization: Geneva, Switzerland, 2011; pp. 1–6.

37. Thurnham, D.I.; Mccabe, L.D.; Haldar, S.; Wieringa, F.T.; Northrop-clewes, C.A.; Mccabe, G.P. Adjusting Plasma Ferritin Concentrations to Remove the Effects of Subclinical Inflammation in the Assessment of Iron Deficiency. *Am. J. Clin. Nutr.* **2010**, *92*, 546–555. [CrossRef]

38. Thurnham, D.I.; McCabe, G.P.; Northrop-Clewes, C.A.; Nestel, P. Effects of Subclinical Infection on Plasma Retinol Concentrations and Assessment of Prevalence of Vitamin A Deficiency: Meta-Analysis. *Lancet* **2003**, *362*, 2052–2058. [CrossRef]

39. De Pee, S.; Dary, O. Biochemical Indicators of Vitamin A Deficiency: Serum Retinol and Serum Retinol Binding Protein. *J. Nutr.* **2002**, *132*, 2895s–2901s. [CrossRef]

40. Tanumihardjo, S.A. Vitamin A: Biomarkers of Nutrition for Development 1–4. *Am. J. Clin. Nutr.* **2011**, *94*, 658–665. [CrossRef]

41. Cook, J.D.; Flowers, C.H.; Skikne, B.S. The Quantitative Assessment of Body Iron. *Blood* **2003**, *101*, 3359–3364. [CrossRef]

42. Cichon, B.; Fabiansen, C.; Iuel-Brockdorf, A.S.; Yaméogo, C.W.; Ritz, C.; Christensen, V.B.; Filteau, S.; Briend, A.; Michaelsen, K.F.; Friis, H. Impact of Food Supplements on Hemoglobin, Iron Status, and Inflammation in Children with Moderate Acute Malnutrition: A 2 × 2 × 3 Factorial Randomized Trial in Burkina Faso. *Am. J. Clin. Nutr.* **2018**, *107*, 278–286. [CrossRef]

43. Rosado, J.L.; González, K.E.; Caamaño, M.D.C.; García, O.P.; Preciado, R.; Odio, M. Efficacy of Different Strategies to Treat Anemia in Children: A Randomized Clinical Trial. *Nutr. J.* **2010**, *9*, 1–10. [CrossRef]
44. Savage, D.; Gangaidzo, I.; Lindenbaum, J.; Kiire, C.; Mukiibi, J.M.; Moyo, A.; Gwanzura, C.; Mudenge, B.; Bennie, A.; Sitima, J.; et al. Vitamin B12 Deficiency Is the Primary Cause of Megaloblastic Anaemia in Zimbabwe. *Br. J. Haematol.* **1994**, *86*, 844–850.
[CrossRef]

45. Chaparro, C.M.; Suchdev, P.S. Anemia Epidemiology, Pathophysiology, and Etiology in Low- and Middle-Income Countries. *Ann. NY Acad. Sci.* **2019**, *1450*, 15–31. [CrossRef]

46. Fishman, S.M.; Christian, P.; West, K.P. The Role of Vitamins in the Prevention and Control of Anaemia. *Public Health Nutr.* **2000**, *3*, 125–150. [CrossRef] [PubMed]

47. Tangpricha, E.M.S. and V. Vitamin D and Anemia: Insights into an Emerging Association. *Curr. Opin. Endocrinol. Diabetes Obes.* **2015**, *22*, 432–438. [CrossRef]

48. Crane, R.J.; Jones, K.D.J.; Trust, K.-W.; Programme, R.; Kilifi, K.; Berkley, J.A. Environmental Enteric Dysfunction: An Overview. *Food Nutr. Bull.* **2015**, *36*, S76–S87. [CrossRef] [PubMed]

49. Cowardin, C.A.; Syed, S.; Iqbal, N.; Jamil, Z.; Sadiq, K.; Iqbal, J.; Ali, S.A.; Moore, S.R. Environmental Enteric Dysfunction: Gut and Microbiota Adaptation in Pregnancy and Infancy. *Nat. Rev. Gastroenterol. Hepatol.* **2022**. [CrossRef]

50. Tickell, K.D.; Atlas, H.E.; Walson, J.L. Environmental Enteric Dysfunction: A Review of Potential Mechanisms, Consequences and Management Strategies. *BMC Med.* **2019**, *17*, 181. [CrossRef]

51. Gilmartin, A.A.; Petri, W.A. Exploring the Role of Environmental Enteropathy in Malnutrition, Infant Development and Oral Vaccine Response. *Philos. Trans. R. Soc. B Biol. Sci.* **2015**, *370*, 20140143. [CrossRef]

52. Budge, S.; Parker, A.H.; Hutchings, P.T.; Garbutt, C. Environmental Enteric Dysfunction and Child Stunting. *Nutr. Rev.* **2019**, *77*, 240–253. [CrossRef]

53. Donangelo, C.M.; Woodhouse, L.R.; Mertz, S.D.; Viteri, F.E.; King, J.C. Human Nutrition and Metabolism Supplemental Zinc Lowers Measures of Iron Status in Young Women with Low Iron Reserves. *J Nutr.* **2002**, *132*, 1860–1864. [CrossRef]

54. Whittae, P. Iron and Zinc interaction in humans. *Am. J. Clin. Nutr.* **1998**, *68*, 442s–446s.

55. Solomons, N.W. Competitive Interaction of Iron and Zinc in the Diet: Consequences for Human Nutrition. *Amr. Inst. Nutr.* **1986**, *116*, 927–935. [CrossRef]

56. Wieringa, F.T.; Dijkhuizen, M.A.; West, C.E. Iron and Zinc Interactions. Letter to Editor. *Am. J. Clin. Nutr.* **2004**, *80*, 787–788. [CrossRef]

57. Lönnerdal, B. Excess Iron Intake as a Factor in Growth, Infections, and Development of Infants and Young Children. *Am. J. Clin. Nutr.* **2017**, *106*, 1681–1688. [CrossRef]

58. Tanumihardjo, S.A.; Russell, R.M.; Stephensen, C.B.; Gannon, B.M.; Craft, N.E.; Haskell, M.J.; Lietz, G.; Schulze, K.; Raiten, D.J. Biomarkers of Nutrition for Development (BOND)-Iron Review. *J. Nutr.* **2016**, *148*, 1001S–1067S. [CrossRef]

59. Moustiés, C.; Bourlieu-Lacanal, C.; Hemery, Y.M.; Bareá, B.; Villeneuve, P.; Servent, A.; Alter, P.; Lebrun, M.; Laillou, A.; Wieringa, F.T.; et al. Nutritional Quality of Ready-to-Use Therapeutic Foods: Focus on Lipid Composition and Vitamin Content. *OCL* **2022**, *29*, 13. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.